Yahoo Finance

Daré Bioscience Announces Return of Rights to Ovaprene®; Phase 3 Program Ongoing; Positive Interim Data and Grant Funding Position Asset for Value-Maximization

SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science ...
Yahoo Finance

Daré Bioscience Reports Full Year 2025 Financial Results and Provides Business Update

SAN DIEGO, March 26, 2026 (GLOBE NEWSWIRE)-- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science ...
Seeking Alpha

Daré Bioscience, Inc. (DARE) Q4 2025 Earnings Call Transcript

Welcome to the conference call hosted by Dare Bioscience to review the company's 2025 financial results and to review -- provide a business update. This call is being recorded. My name is Desiree, and ...
Seeking Alpha

Daré Bioscience, Inc. (DARE) Q2 2025 Earnings Call Transcript

Welcome to the conference call hosted by Daré Bioscience Therapeutics Company's Second Quarter 2025 Financial Results and to provide a business update. This call is being recorded. My name is [ ...